Overview

Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, multi-cohort Phase III clinical trial. It primarily enrolls high-risk recurrent esophageal cancer patients who have undergone R0 resection after neoadjuvant chemoimmunotherapy. Eligible patients are stratified based on pathological lymph node status and receive either toripalimab monotherapy as maintenance treatment or clinical observation only.
Phase:
PHASE3
Details
Lead Sponsor:
Henan Cancer Hospital